Imaging HER2 in advanced lung cancer with a special PET scan
Part of Cancer, Lungs & breathing clinical trials.
This study tests an imaging technique that uses a special tracer to attach to HER2 (a protein on some cancer cells) and make it visible on a PET/CT scan. The goal is to see if the tracer can help doctors understand where HER2 is in the body, which may guide future treatment options for advanced lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and able to follow the study plan.
- Your lung cancer is advanced (has spread) and shows a specific change called HER2 — either a mutation or too much of the HER2 protein.
- Your cancer has gotten worse after at least one round of platinum-based chemotherapy, with or without immunotherapy.
- You have at least two tumors that are 2 cm or larger, and you can have a PET/CT scan.
- You can provide a tissue sample (biopsy) from your most recent cancer treatment.
- You are generally well enough to be up and about (ECOG score 0 or 1) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging method to see if a special 'tracer' can light up tumors that have a protein called PD-L1, which is a target for immunotherapy. By taking a PET scan, doctors hope to predict whether immunotherapy will work for you.
This study uses a special PET/CT scan to measure a protein called HER3 in your tumors. The scan uses a radioactive version of the drug patritumab deruxtecan (HER3-DXd). This test may help doctors understand how much HER3 is in your cancer and decide if HER3-targeted therapy could work for you.
This trial tests whether a new imaging agent called TGW211 can help doctors see HER2-positive cancers more clearly on scans. It may lead to better ways to track these cancers in the future.
This early-phase study uses a special PET scan with a drug tagged for imaging to predict how well HER2-targeted treatments will work. It may help doctors choose the most effective therapy for HER2-positive breast cancer.
This study uses a radioactive tracer to see how much HER2 protein is on your breast cancer cells. The scan may help doctors understand the type of HER2 you have and choose the best treatment.
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.